are to:
Drive sales of pralatrexate in the United States.
We have established a commercial organization to drive sales of pralatrexate in the United States. We began making pralatrexate available for commercial sale in the United States on October 5, 2009 and commenced our commercial launch in January 2010.
Obtain regulatory approval to market pralatrexate in foreign jurisdictions.
In May 2011, Allos Therapeutics and Mundipharma International Corporation Limited (Mundipharma) entered into a strategic collaboration agreement to co-develop FOLOTYN. Under the agreement, Allos retains full commercialization righs for FOLOTYN in the United States and Canada, with Mundipharma having exclusive rights to commercialize pralatrexate in all other countries. Allos and Mundipharma are currently pursuing regulatory approval to market FOLOTYN in the European Union for relapsed or refractory PTCL and are developing FOLOTYN in other potential indications. Allos' Marketing Authorisation Application (MAA) was accepted for review by the European Medicines Agency (EMA) in December 2010.
Advance our pralatrexate clinical development program.
We are committed to evaluating pralatrexate for oncology use as a single agent and in combination with other therapies. We currently have ongoing clinical trials involving pralatrexate in multiple indications and plan to initiate additional trials in the future to evaluate pralatrexate's potential clinical utility in other hematologic malignancies and solid tumor indications.
Focus on the oncology market.
We intend to continue to focus our drug development and commercialization efforts on the oncology market. We believe the oncology market is attractive due to its size, demand for safer and more effective cancer treatments, relatively small physician population that can be addressed with a targeted sales force and potential for expedited regulatory review.
Expand our product portfolio.
We may pursue opportunities from time to time to expand our product portfolio by identifying and evaluating new compounds that have demonstrated potential in preclinical or clinical studies and are strategically aligned with our existing oncology portfolio. Our intent is to build a portfolio of proprietary product candidates that have the potential to improve the standard of care in cancer therapy and provide commercial, regulatory and/or geographic exclusivity.